Bepridil is potent against SARS-CoV-2 In Vitro. Academic Article uri icon

abstract

  • Guided by a computational docking analysis, about 30 FDA/EMA-approved small molecule medicines were characterized on their inhibition of the SARS-CoV-2 main protease (MPro). Of these tested small molecule medicines, six displayed an IC50 value in inhibiting MPro below 100 M. Three medicines pimozide, ebastine, and bepridil are basic small molecules. Their uses in COVID-19 patients potentiate dual functions by both raising endosomal pH to slow SARS-CoV-2 entry into the human cell host and inhibiting MPro in infected cells. A live virus-based microneutralization assay showed that bepridil inhibited cytopathogenic effect induced by SARS-CoV-2 in Vero E6 cells completely at and dose-dependently below 5 M and in A549 cells completely at and dose-dependently below 6.25 M. Therefore, the current study urges serious considerations of using bepridil in COVID-19 clinical tests.

published proceedings

  • bioRxiv

altmetric score

  • 74

author list (cited authors)

  • Vatansever, E. C., Yang, K., Kratch, K. C., Drelich, A., Cho, C., Mellott, D. M., ... Liu, W. R.

citation count

  • 36

complete list of authors

  • Vatansever, Erol C||Yang, Kai||Kratch, Kaci C||Drelich, Aleksandra||Cho, Chia-Chuan||Mellott, Drake M||Xu, Shiqing||Tseng, Chien-Te K||Liu, Wenshe Ray

publication date

  • July 2020